A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Brief description of study

This study being done: • To understand how the body absorbs and processes different doses of TTI-621 • To understand how TTI-621 affects your body, such as its effect on your immune system. • To understand the side effects and possible benefit when TTI-621 is given alone and also together with different FDA approved anti-cancer treatments


Clinical Study Identifier: s18-00690
ClinicalTrials.gov Identifier: NCTs18-00690


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.